Ranbaxy Laboratories Ltd., is a research-based, international
pharmaceutical company located in India. In addition to being a dominant player
in the area of developing generic medicines, Ranbaxy has committed to investing
in drug discovery. Keeping in mind the highly complex, cost-intensive and
failure-prone nature of drug discovery, Ranbaxy has evolved an alliance-centric
business model to bring sustainability to its drug discovery effort. Ranbaxy has entered
into alliance with partners at different stages of drug discovery and
development. A partnership with Promega is an effort to access robust assays
that can assist Ranbaxy in hit identification and lead optimization during early
drug discovery stages. Here we describe our characterization of the DPPIV-GLO™
Protease Assay.
Cell Notes 23, 6–9.
Joseph Alex Davis, Vamshi Krishna Tulasi Abhijit Ray, and Pradip Bhatnagar
How to Cite This Article
Davis, J. A., Ray, V. K. T. A and Bhatnagar, P.
Detection of dipeptidyl peptidase activity with DPPIV-Glo™ Assay.
[Internet] 2009. [cited: year, month, date]. Available from:
http://au.promega.com/resources/articles/pubhub/cellnotes/detection-of-dipeptidyl-peptidase-activity-with-dppiv-glo-assay/
Davis, J. A., Ray, V. K. T. A and Bhatnagar, P.
Detection of dipeptidyl peptidase activity with DPPIV-Glo™ Assay.
Promega Corporation Web site.
http://au.promega.com/resources/articles/pubhub/cellnotes/detection-of-dipeptidyl-peptidase-activity-with-dppiv-glo-assay/
Updated 2009.
Accessed Month Day, Year.